Berlin – In conjunction with the management team, capiton has acquired 85% of the shares in KD Pharma Bexbach GmbH from the Bioseutica Group, which is retaining a 15% stake. The parties have not disclosed the purchase price.
KD Pharma Bexbach GmbH is a leading manufacturer of highly-enriched Omega-3 fatty acids, used as ingredients for food supplements and increasingly for medicines. KD Pharma Bexbach GmbH's unique patented production technology enables it to manufacture particularly high concentrations of Omega-3 fatty acids at up to 99% purity.
capiton is additionally investing a significant amount in expanding the production facilities at KD Pharma Bexbach GmbH, which are currently running at full capacity, with the aim of boosting capacity several fold over the next 12 months.
A team led by Berlin-based corporate law partner Ralf Kurney advised capiton on all legal aspects of the transaction. capiton is a longstanding CMS Hasche Sigle client.
capiton is an independent owner-managed private equity firm that supports established SMEs as an equity capital provider in the context of growth finance and management buy-outs.
CMS Hasche Sigle
Ralf Kurney, Corporate/M&A, Lead Partner
Christian Plodeck, Corporate/M&A
Dr Igor Stenzel, Corporate/M&A
Dr Tobias Teicke, Corporate/Compliance
Dr Jens Moraht, Finance
Jens Benninghofen, Finance
Prof. Winfried Bullinger, Patent Law
Dr Kai Hermes, Patent Law
Jesko Nobiling, Tax
Dr Nadja Fleischmann, Real Estate
Press Contact
presse@ms-hs.com
